Compare Merck & Co., Inc. (MRK) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Workiva Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Workiva Inc trades at $72.76 (market cap $4.01B). The key difference: Merck & Co., Inc. is far larger — about 91.3× Workiva Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| MRK | WK | |
|---|---|---|
Market Cap | $366.28B | $4.01B |
Sector | Health | Technology |
52-Week High | $156.43 | $93.31 |
52-Week Low | $77.60 | $44.31 |
Enterprise Value | $413.04B | $3.99B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Workiva (WK) trades at $73.71, down 3.71% today, showing technical support near $72 with bullish moving averages. The company demonstrates strong revenue growth, with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and high analyst buy ratings (89%) support optimism, though elevated valuation ratios (P/E 87.75) warrant caution.
Outlook remains positive with consistent earnings beats and AI product launches driving growth. Key risks include high valuation multiples and competitive pressures in the SaaS sector. The consensus price target of $82.50 suggests 12% upside potential from current levels, supported by institutional accumulation and strong operational cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
